The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The 2008 American College of Rheumatology guidelines for the treatment of rheumatoid arthritis advises laboratory monitoring at baseline and then every 2–4 weeks with the first 3 months, every 8–12 weeks for 3–6 months, and then every 12 weeks beyond 6 months of treatment.194”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [194]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251
Zhang, W., Doherty, M., Leeb, B. F., Alekseeva, L., Arden, N. K., Bijlsma, J. W., Dinçer, F., Dziedzic, K., Häuselmann, H. J., Herrero-Beaumont, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062091 · Cited by 1,338
The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases
Aletaha, D., & Smolen, J. S. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2005.09.005 · Cited by 152
Research works printed but not linked: 248
- 10.1001/jama.289.24.3229 · DOI
- 10.1056/NEJMct055183 · DOI · Paper page
- 10.1002/art.10148 · DOI · Paper page
- Fitch K, 2001, The RAND/UCLA Appropriateness Method user's manual
- Wells GA, 1999, The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta‐analyses
- 10.1136/ard.2004.028886 · DOI · Paper page
- 10.1002/art.21235 · DOI · Paper page
- 10.1002/art.1780380602 · DOI · Paper page
- Pincus T, 2005, The American College of Rheumatology (ACR) core data set and derivative “patient only” indices to assess rheumatoid arthritis, Clin Exp Rheumatol, 23, S109
- Wells GA, 2005, Minimal disease activity for rheumatoid arthritis: a preliminary definition, J Rheumatol, 32, 2016
- Wolfe F, 2005, A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS‐II), J Rheumatol, 32, 2410
- 10.1002/art.21494 · DOI
- 10.1007/s10067-006-0275-5 · DOI
- 10.1007/s10067-006-0343-x · DOI
- 10.1136/ard.2005.041376 · DOI · Paper page
- 10.1136/ard.62.2.120 · DOI · Paper page
- 10.1136/ard.62.5.427 · DOI
- 10.1136/ard.61.4.290 · DOI · Paper page
- 10.1136/ard.2003.010611 · DOI
- 10.1136/ard.62.7.611 · DOI
- 10.1136/ard.61.12.1055 · DOI
- 10.1136/ard.36.3.274 · DOI
- Cohen JD, 2006, Health Assessment Questionnaire score is the best predictor of 5‐year quality of life in early rheumatoid arthritis, J Rheumatol, 33, 1936
- 10.1093/rheumatology/32.8.717 · DOI
- 10.1136/ard.45.5.373 · DOI
- 10.1002/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R · DOI
- 10.1002/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G · DOI
- 10.1093/rheumatology/32.10.899 · DOI
- 10.1016/j.jamcollsurg.2005.07.009 · DOI
- 10.1177/0272989X04264212 · DOI
- 10.1016/S0895-4356(01)00365-1 · DOI
- Hunt SA, 2005, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure), Circulation, 112, e154
- 10.1093/rheumatology/kei024 · DOI
- 10.1185/030079906X80341 · DOI
- Wendt T, 1999, Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis, Eur J Med Res, 4, 442
- 10.1002/art.1780340805 · DOI
- 10.1002/art.21018 · DOI
- 10.1016/0049-0172(91)90047-4 · DOI
- Rau R, 1991, A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis, J Rheumatol, 18, 328
- 10.1136/ard.58.4.220 · DOI · Paper page
- 10.1093/rheumatology/36.10.1082 · DOI
- 10.1002/art.1780350802 · DOI
- 10.1093/rheumatology/33.11.1049 · DOI
- 10.1056/NEJM199605163342002 · DOI
- 10.1001/archinte.159.21.2542 · DOI · Paper page
- 10.7326/0003-4819-137-9-200211050-00007 · DOI · Paper page
- 10.1002/art.1780381111 · DOI · Paper page
- 10.1016/S0140-6736(98)09403-3 · DOI · Paper page
- 10.1093/rheumatology/30.6.451 · DOI
- 10.1016/S0002-9343(99)80399-4 · DOI
- 10.7326/0003-4819-119-11-199312010-00002 · DOI
- 10.1002/1529-0131(200110)44:10<2235::AID-ART385>3.0.CO;2-A · DOI
- 10.1136/ard.48.5.389 · DOI
- 10.7326/0003-4819-122-2-199501150-00001 · DOI · Paper page
- 10.1002/art.1780370505 · DOI
- 10.1002/art.1780400510 · DOI
- 10.1002/art.1780310602 · DOI
- 10.1136/ard.60.10.913 · DOI
- Kalden JR, 2001, Improved functional ability in patients with rheumatoid arthritis: longterm treatment with leflunomide versus sulfasalazine, J Rheumatol, 28, 1983
- The Australian Multicentre Clinical Trial Group, 1992, Sulfasalazine in early rheumatoid arthritis, J Rheumatol, 19, 1672
- 10.1007/BF02208150 · DOI
- 10.1002/art.10228 · DOI
- Hurst S, 2002, Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects, J Rheumatol, 29, 1639
- 10.1016/S0140-6736(97)01300-7 · DOI · Paper page
- 10.1002/art.21519 · DOI · Paper page
- 10.1002/art.20712 · DOI · Paper page
- 10.1002/art.20568 · DOI · Paper page
- 10.7326/0003-4819-146-6-200703200-00005 · DOI · Paper page
- 10.1056/NEJM200011303432201 · DOI · Paper page
- 10.1002/art.21405 · DOI · Paper page
- 10.1002/art.10308 · DOI · Paper page
- Baumgartner SW, 2004, Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability, J Rheumatol, 31, 1532
- Genovese MC, 2005, Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis, J Rheumatol, 32, 1232
- 10.1002/1529-0131(200010)43:10<2316::AID-ANR20>3.0.CO;2-6 · DOI
- 10.1016/S0002-9343(02)01243-3 · DOI
- Choi HK, 2002, A cost effectiveness analysis of treatment options for methotrexate‐naive rheumatoid arthritis, J Rheumatol, 29, 1156
- 10.1136/ard.2005.038349 · DOI
- 10.1016/S0140-6736(04)15640-7 · DOI · Paper page
- 10.1002/art.11142 · DOI
- 10.7326/0003-4819-130-6-199903160-00004 · DOI · Paper page
- 10.1196/annals.1254.057 · DOI
- O'Dell JR, 2006, Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis, J Rheumatol, 33, 213
- 10.1111/j.1445-5994.2006.01170.x · DOI
- 10.1002/art.11027 · DOI
- 10.1136/ard.2005.035709 · DOI
- 10.1136/ard.2003.013052 · DOI · Paper page
- 10.1016/S0149-2918(03)80164-9 · DOI · Paper page
- 10.1136/ard.61.4.358 · DOI
- 10.1093/rheumatology/keh508 · DOI
- Furst DE, 2003, Adalimumab, a fully human anti tumor necrosis factor‐α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis), J Rheumatol, 30, 2563
- 10.1002/art.20228 · DOI
- 10.1136/ard.2006.051540 · DOI
- 10.1002/art.20217 · DOI · Paper page
- 10.1016/S0140-6736(99)05246-0 · DOI · Paper page
- 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W · DOI
- 10.1002/art.20159 · DOI · Paper page
- 10.1136/ard.2003.015933 · DOI
- 10.1016/j.amjmed.2005.01.029 · DOI
- 10.1056/NEJM200011303432202 · DOI · Paper page
- 10.1002/art.20982 · DOI · Paper page
- 10.1002/art.21655 · DOI · Paper page
- 10.1056/NEJM199901283400401 · DOI · Paper page
- 10.1136/ard.2005.044404 · DOI
- 10.1002/art.10697 · DOI · Paper page
- 10.1002/art.20221 · DOI · Paper page
- 10.1136/ard.2005.049650 · DOI
- Emery P, 2006, Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health‐related quality of life, J Rheumatol, 33, 681
- Genant HK, 2006, Abatacept sustains inhibition of radiographic progression over 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate: results from the long‐term extension of the AIM trial, Ann Rheum Dis, 65, 57
- 10.7326/0003-4819-144-12-200606200-00003 · DOI · Paper page
- 10.1002/art.21778 · DOI · Paper page
- 10.1136/ard.2004.029694 · DOI · Paper page
- 10.1002/art.22070 · DOI · Paper page
- 10.1002/art.21978 · DOI · Paper page
- 10.1002/art.21568 · DOI · Paper page
- 10.1002/art.20009 · DOI · Paper page
- 10.1001/jama.295.19.2275 · DOI · Paper page
- 10.1002/art.21386 · DOI · Paper page
- 10.1002/art.21137 · DOI · Paper page
- 10.1016/S0755-4982(05)83925-9 · DOI
- 10.1086/506935 · DOI · Paper page
- 10.1136/ard.62.suppl_2.ii30 · DOI
- 10.1056/NEJMoa011110 · DOI · Paper page
- 10.1086/421494 · DOI · Paper page
- Perdriger A, 2006, Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice, J Rheumatol, 33, 865
- 10.1136/ard.2005.043166 · DOI · Paper page
- McKendry RJ, 1988, Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a case‐control study of 131 patients, Arch Intern Med, 149, 685, 10.1001/archinte.1989.00390030137027 · DOI
- 10.1093/rheumatology/39.12.1374 · DOI
- 10.1093/rheumatology/39.6.655 · DOI · Paper page
- 10.1093/rheumatology/keh512 · DOI
- 10.1007/BF02114393 · DOI
- 10.1093/rheumatology/28.2.147 · DOI
- 10.1007/BF00302669 · DOI
- Buchbinder R, 1993, Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice, J Rheumatol, 20, 639
- 10.1378/chest.109.4.933 · DOI
- 10.1093/rheumatology/35.5.441 · DOI
- Ohosone Y, 1997, Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis, J Rheumatol, 24, 2299
- 10.1002/art.1780290713 · DOI
- Tan N, 1993, Oral methotrexate in the treatment of Felty's syndrome, J Rheumatol, 20, 599
- 10.1093/rheumatology/37.8.908 · DOI
- 10.1136/ard.2004.033241 · DOI · Paper page
- 10.1136/ard.2004.023473 · DOI
- 10.1136/ard.2004.030528 · DOI · Paper page
- 10.1136/ard.61.9.793 · DOI · Paper page
- Louis M, 2003, Induction of autoantibodies during prolonged treatment with infliximab, J Rheumatol, 30, 2557
- 10.1002/art.20311 · DOI · Paper page
- The Criteria Committee of the New York Heart Association, 1994, Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 253
- 10.1161/01.CIR.0000077913.60364.D2 · DOI · Paper page
- 10.1161/01.CIR.0000124490.27666.B2 · DOI · Paper page
- 10.1080/030097499750042245 · DOI
- 10.1002/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B · DOI
- Cartwright VW, 2003, Methotrexate, laboratory testing and risk of serious illness: analyses in 20,000 patients, Arthritis Rheum, 48, S428
- Rau R, 1989, Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate, J Rheumatol, 16, 489
- Yazici Y, 2005, Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities, Clin Exp Rheumatol, 23, 517
- 10.1136/ard.2004.023408 · DOI
- 10.1093/rheumatology/29.2.120 · DOI
- 10.1136/ard.60.6.566 · DOI
- Morassut P, 1989, Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis: a randomized, double blind 26‐week trial, J Rheumatol, 16, 302
- Suarez‐Almazor ME, 1988, A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis, J Rheumatol, 15, 753
- 10.1002/art.1780360303 · DOI
- 10.1093/rheumatology/36.3.345 · DOI
- 10.1093/rheumatology/37.10.1060 · DOI
- Cannon GW, 2004, Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD, J Rheumatol, 31, 1906
- 10.1002/art.20167 · DOI
- Sany J, 1991, Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases, J Rheumatol, 18, 1323
- 10.1002/art.1780330305 · DOI
- 10.1007/BF02030344 · DOI
- 10.1136/ard.47.8.654 · DOI
- 10.1007/BF02330596 · DOI
- 10.1016/0002-9343(85)90312-2 · DOI
- 10.1002/art.1780371013 · DOI
- McKendry RJ, 1993, Adverse effects of low dose methotrexate therapy in rheumatoid arthritis, J Rheumatol, 20, 1850
- 10.1007/BF00290521 · DOI
- Andersen LS, 1997, Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: relation to withdrawal and side effects, J Rheumatol, 24, 830
- 10.1093/rheumatology/33.7.651 · DOI
- 10.1136/ard.62.4.291 · DOI
- 10.3109/03009749509095176 · DOI
- Jones E, 1991, Response to sulfasalazine in rheumatoid arthritis: life table analysis of a 5‐year followup, J Rheumatol, 18, 195
- 10.1002/hep.1840040313 · DOI · Paper page
- 10.1016/S0011-3840(64)80003-4 · DOI
- 10.1007/s10067-006-0218-1 · DOI
- 10.1136/gut.35.4.569 · DOI
- Koziel MJ, 1992, Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis, J Immunol, 149, 3339, 10.4049/jimmunol.149.10.3339 · DOI · Paper page
- 10.1111/j.1478-3231.2006.01339.x · DOI
- 10.1128/JVI.77.4.2469-2476.2003 · DOI
- 10.1111/j.1440-1746.2006.04559.x · DOI
- Nagashima M, 2005, The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis: epidemiology of DMARDs treatment in Japan, Clin Exp Rheumatol, 23, 27
- Furst DE, 1989, Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis, J Rheumatol, 16, 313
- Ostensen M, 2006, Anti‐inflammatory and immunosuppressive drugs and reproduction, Arthritis Res Ther, 8, 209, 10.1186/ar1957 · DOI
- 10.3109/00016348709022049 · DOI
- 10.1046/j.1365-2133.1996.134869.x · DOI
- 10.1016/0002-9378(72)90824-1 · DOI
- 10.1038/ncprheum0532 · DOI
- Chakravarty EF, 2003, The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes, J Rheumatol, 30, 241
- 10.1007/s10620-006-9452-2 · DOI
- 10.1111/j.1572-0241.2004.30186.x · DOI · Paper page
- 10.1111/j.1365-2036.2005.02405.x · DOI · Paper page
- 10.1038/sj.jp.7211481 · DOI
- 10.1093/rheumatology/kel400 · DOI
- 10.1034/j.1600-0897.2001.d01-25.x · DOI
- 10.1016/j.semarthrit.2005.05.002 · DOI
200 of 248 shown
Cited by
Hochberg, M. C., Altman, R. D., April, K. T., Benkhalti, M., Guyatt, G., McGowan, J., Towheed, T., Welch, V., Wells, G., & Tugwell, P. (2012) · Arthritis Care & Research · doi:10.1002/acr.21596 · Cited by 3,068
Self-citationLow-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001259 · Cited by 430
Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.018 · Cited by 368
Metadata
- Authors
- Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., Outman, R., Allison, J. J., Almazor, M. S., Bridges, S. L., Chatham, W. W., Hochberg, M., Maclean, C., Mikuls, T., Moreland, L. W., O'dell, J., Turkiewicz, A. M., & Furst, D. E.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2008-05-30
- Volume
- 59
- Issue
- 6
- Pages
- 762-784
- ISSN
- 0893-7524
- 1529-0123
- Cited by
- 1,157
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.23721
- The paper
- Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., Outman, R., Allison, J. J., Almazor, M. S., Bridges, S. L., Chatham, W. W., Hochberg, M., Maclean, C., Mikuls, T., Moreland, L. W., . . . Furst, D. E. (2008). American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care & Research. https://doi.org/10.1002/art.23721
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.